Brady Collins
Before the polio vaccine was developed, parents were terrified of the disease, which primarily impacted affluent children. They avoided public gatherings, pools, and fairs, and kept their children away from new friends. When the vaccine was licensed in 1955, the country celebrated, and its inventor, Jonas Salk, became an overnight hero. However, it is unclear whether parents rushed to vaccinate their children, as there is no specific information about this. Large-scale clinical trials in the Soviet Union and Czechoslovakia in the late 1950s proved the vaccine's safety and efficacy, and by 1961, polio cases in the US had dropped to 161.
| Characteristics | Values |
|---|---|
| Date of first polio vaccine development | 1955 |
| Name of the scientist who developed the first polio vaccine | Jonas Salk |
| Number of annual polio cases in the US before the vaccine | 16,000 |
| Number of annual polio cases in the US in 2023 | 0 |
| Number of annual polio cases worldwide before the vaccine | 350,000 |
| Number of annual polio cases worldwide in 2018 | 33 |
| Countries where polio is still endemic | Pakistan and Afghanistan |
| Countries where the Global Alliance for Vaccines and Immunization supplies the inactivated polio vaccine | Developing countries |
| Cost of the inactivated polio vaccine supplied by the Global Alliance for Vaccines and Immunization | €0.75 (about US$0.89) per dose |
| Number of doses of the oral polio vaccine (OPV) that can cause paralysis | About 1 out of every 2.4 million |
| Number of doses of the inactivated polio vaccine (IPV) that can cause a serious allergic reaction | About 1 out of every 1 million |
| Number of doses of the polio vaccine recommended for children by the CDC | 4 |
| Number of doses of the polio vaccine recommended for unvaccinated adults by the CDC | 3 |
Explore related products
What You'll Learn
- Polio epidemics caused widespread fear and avoidance of public spaces
- The first polio vaccine was developed by Jonas Salk in the early 1950s
- Salk's inactivated polio vaccine was licensed in 1955, with mass trials preceding this
- Albert Sabin developed the oral polio vaccine, which was licensed in the US
- The World Health Organization recommends all children be fully vaccinated against polio
Polio epidemics caused widespread fear and avoidance of public spaces
Before the polio vaccine was developed, several polio epidemics occurred between 1948 and 1955. The fear of contracting polio was so widespread that many people avoided public spaces and gatherings such as fairs, sports games, and swimming pools. Parents were afraid to let their children play with new friends and regularly checked them for symptoms. Those who contracted polio were often treated in isolation wards at hospitals, and in severe cases, patients whose breathing muscles were paralysed were placed in large machines called iron lungs to help them breathe.
The first successful polio vaccine was created by US physician Jonas Salk in the early 1950s. Salk first tested the vaccine on himself and his family in 1953 and then on 1.6 million children in Canada, Finland, and the USA in 1954. The results were announced, and the inactivated polio vaccine (IPV) was licensed on April 12, 1955. This marked a turning point in the fight against polio, as annual cases in the United States dropped significantly from 58,000 to 5,600 by 1957, and further down to 161 cases by 1961.
The development of the polio vaccine was a collaborative effort, with other researchers also making significant contributions. Albert Sabin, a physician and microbiologist, developed the oral polio vaccine (OPV), which was a live-attenuated vaccine given orally as drops or on a sugar cube. Hilary Koprowski conducted the first test of a live-attenuated vaccine on humans in 1950, and further trials took place in what is now the Democratic Republic of the Congo. Large-scale clinical trials in the Soviet Union in the late 1950s to early 1960s demonstrated the safety and high efficacy of the Sabin vaccine, leading to its worldwide distribution.
The success of the polio vaccines led to the first modern mass inoculations, and polio was eliminated from the Americas by 1994 and Europe by 2002. Today, the World Health Organization (WHO) recommends that all children be fully vaccinated against polio with either the IPV or OPV. These vaccines have successfully reduced the number of cases reported each year from an estimated 350,000 in 1988 to 33 in 2018. While vaccine-associated paralytic polio is an extremely rare complication, affecting about 1 in every 2.4 million doses, the benefits of vaccination greatly outweigh the risks.
How Vaccines Treated Elizabeth's Pneumococcal Bacteremia
You may want to see also
Explore related products
The first polio vaccine was developed by Jonas Salk in the early 1950s
In the early 1950s, the first successful polio vaccine was developed by US physician Jonas Salk. Before the polio vaccine, the disease was a major cause of disability in children, with around 16,000 cases of polio occurring each year in the US in the 20th century. Polio is a highly infectious disease that mostly affects young children and can lead to paralysis and even death.
Salk's experimental killed-virus vaccine was first tested on himself and his family in 1953, and then on 1.6 million children in Canada, Finland, and the USA in 1954. The results were announced on April 12, 1955, and Salk's inactivated polio vaccine (IPV) was licensed on the same day. The federal government immediately implemented a plan to distribute the vaccine to children across the country.
The impact of Salk's vaccine was significant. By 1957, annual cases of polio in the US had dropped from 58,000 to 5,600, and by 1961, only 161 cases remained. Within a year of the vaccine's release, deaths attributed to polio had declined by 50%, and this downward trend has continued, with polio now eradicated in most of the world.
Salk was committed to equitable access to his vaccine and understood that elimination efforts would require universal low- or no-cost vaccination. The World Health Organization (WHO) recommends that all children be fully vaccinated against polio, and the two available vaccines have been instrumental in reducing the number of cases globally.
Polio Vaccines: Monkey Cells, Past and Present
You may want to see also
Explore related products
Salk's inactivated polio vaccine was licensed in 1955, with mass trials preceding this
Jonas Salk's inactivated polio vaccine (IPV) was licensed in the US on 12 April 1955, one day after its results were announced. The vaccine was developed in the span of 6 years, with Salk testing it on himself and his family in 1953, and on 1.6 million children in Canada, Finland, and the US in 1954. This was the largest clinical trial in history.
The development of the vaccine was rapid due to the urgency of the situation. Polio was a highly infectious disease that mostly affected young children, attacking their nervous systems and causing paralysis and, in some cases, death. Before the vaccine, children affected by polio depended on iron lungs for their survival. In the late 19th and early 20th centuries, frequent epidemics made polio the most feared disease globally. By the mid-20th century, the poliovirus had spread worldwide, killing or paralysing over half a million people annually. With no cure and rising epidemics, there was an urgent need for a vaccine.
The 1954 field trials used a singular statistical design, with over 600,000 schoolchildren injected with the vaccine or a placebo, and over a million others as "observed" controls. This dual protocol demonstrated the power and limitations of randomised clinical trials in legitimising therapeutic claims. The trials were funded by donations from a concerned nation and supported by scientists, staff, and volunteers. Salk's commitment to equitable access to his vaccine was evident, as he understood that elimination efforts would be futile without universal low- or no-cost vaccination.
Following the licensing of Salk's vaccine, mass polio vaccination began in the US. However, soon after, reports emerged of atypical cases of paralytic polio, shaking public trust in the vaccine and leading to a drop in vaccination rates. Public relation campaigns were launched by state health boards to reassure the public and encourage polio vaccination.
McDowell Triplets: Autistic Hours Post-Vaccination?
You may want to see also
Explore related products
Albert Sabin developed the oral polio vaccine, which was licensed in the US
Albert Sabin, a Polish-American medical researcher, developed the oral polio vaccine (OPV). Sabin's approach was to create a live attenuated vaccine for oral administration. This process marked the advent of the oral polio vaccine. Sabin's vaccine was based on mutant strains of the poliovirus that stimulated antibody production without causing paralysis. Sabin tested his vaccine on himself, his family, and colleagues. Sabin's first clinical trials were carried out at the Chillicothe Ohio Reformatory in 1954.
From 1956 to 1960, Sabin worked with Russian colleagues to perfect the oral vaccine and prove its effectiveness and safety. During this period, Sabin's vaccine was tested on millions of children in the Soviet Union, Eastern Europe, Singapore, Mexico, and the Netherlands. The mass vaccination campaign in the Soviet Union demonstrated high vaccine effectiveness, which resulted in the licensure of OPV in the United States in 1961. Sabin's vaccine was easier to administer and more affordable than the existing inactivated polio vaccine (IPV). It became the predominant method of vaccination against polio in the United States for the next three decades.
Sabin refused to patent his vaccine, waiving commercial exploitation and any personal financial gain. His decision ensured a low price for the vaccine, facilitating its widespread adoption. The Sabin Vaccine Institute was founded in 1993 to continue the work of developing and promoting vaccines. Sabin's pioneering contributions to vaccinology were recognized with numerous accolades, including the National Medal of Science in 1970.
The oral polio vaccine played a pivotal role in the global initiative to eradicate polio, led by the World Health Organization (WHO), UNICEF, and the Rotary Foundation. This collaborative effort, launched in 1988, aimed for the permanent reduction of polio to zero, with no risk of reintroduction. The OPV developed by Sabin was instrumental in achieving significant milestones in this initiative. By 1994, polio was eliminated in the Americas, and by 2000, it was certified eradicated in 36 Western Pacific countries, including China and Australia. Europe was declared polio-free in 2002, and in 2014, the entire South-East Asia Region of WHO followed suit.
While Sabin's oral polio vaccine has been largely replaced by genetically stabilized vaccines, it remains a testament to his groundbreaking work in the field of vaccinology. The legacy of Sabin's vaccine continues to inspire and shape global health efforts in the ongoing battle against infectious diseases.
Real Estate Agents: Essential Workers for Vaccines?
You may want to see also
Explore related products
The World Health Organization recommends all children be fully vaccinated against polio
In 1988, the World Health Assembly passed a resolution to eradicate polio, aiming for its permanent reduction to zero with no risk of reintroduction. As a result, the Global Polio Eradication Initiative (GPEI) was launched, and the World Health Organization (WHO) has played a crucial role in supporting global collaboration and expanding vaccine production. WHO recommends that all children be fully vaccinated against polio to ensure maximum protection.
Before the polio vaccine was developed, several epidemics occurred between 1948 and 1955, causing widespread fear and concern. Many people avoided public gatherings and parents restricted their children's social interactions to prevent the spread of the disease. The first successful vaccine was created by US physician Jonas Salk in the early 1950s, and he tested it on himself and his family before larger-scale trials.
Salk's inactivated polio vaccine (IPV) was licensed on April 12, 1955, and it had a significant impact on reducing polio cases. By 1957, annual cases dropped from 58,000 to 5,600, and by 1961, only 161 cases remained. This success led to the development of mass inoculations and the inclusion of polio vaccination in routine childhood immunization schedules.
Oral polio vaccines (OPV) were also developed, including the widely distributed Sabin strains. OPV is typically administered orally in drops or on a sugar cube. While OPV has been effective, there have been rare cases of vaccine-associated paralytic polio (VAPP), occurring in about 1 out of every 2.4 million doses. This happens when the weakened virus in OPV mutates back to its wildtype form.
To address this issue, novel oral polio vaccines like nOPV2 have been developed, aiming to increase vaccine safety and prevent further outbreaks of circulating vaccine-derived polioviruses (cVDPVs). These novel vaccines have greater genetic stability and a reduced likelihood of reverting to a virulent form.
The efforts of WHO and global health initiatives have been tremendously successful. Polio has been eradicated from most of the world, and the number of cases reported annually has drastically dropped from 350,000 in 1988 to 33 in 2018. However, polio remains endemic in countries like Pakistan and Afghanistan, and misconceptions about vaccine safety persist in some regions. Ensuring equitable access to safe and effective polio vaccines remains a priority for WHO and global health organizations.
Vaccines: Stopping the Spread of Infection
You may want to see also
Frequently asked questions
Yes, parents were eager to vaccinate their children against polio when the vaccine was first developed. They had been scared of the polio epidemics that occurred each summer and closely followed vaccine trials.
The first polio vaccine was licensed in the US in 1955, developed by Jonas Salk and his colleagues.
The polio vaccine has been highly effective in reducing the number of cases and eliminating polio from most of the world. By 1957, just two years after the vaccine was licensed, annual cases in the US dropped from 58,000 to 5,600. In 1961, only 161 cases remained.
Yes, there are two types of polio vaccines: inactivated poliovirus (IPV), given by injection, and weakened poliovirus (OPV) or oral polio vaccine, given by mouth.
